




Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to 2022 ACR/EULAR criteria

Jang Woo Ha¹, Jung Yoon Pyo¹, Sung Soo Ahn², Jason Jungsik Song^{1,3}, Yong-Beom Park^{1,3}, and Sang-Won Lee^{1,3}

¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul; ²Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin; ³Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea

Overlap syndrome of systemic sclerosis with ANCA-associated vasculitis according to 2022 ACR/EULAR criteria



Conclusion

we suggest that physicians should perform ANCA tests in SSc patients exhibiting signs suggestive of small- or medium-vessel vasculitis and apply the new criteria for AAV.

Background/Aims: This study applied the 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) to patients with systemic sclerosis (SSc) and investigated the frequency of overlap syndrome of SSc and AAV (SSc-AAV-OS).

Methods: Among the 232 patients diagnosed with SSc, 105 with signs suggestive of small- or medium-vessel vasculitis, which were defined as the present of interstitial lung disease (ILD), peripheral neuropathy, or suspected renal vasculitis, were included in this study and analyzed.

Results: Among the 105 SSc patients, the detection rate of ANCA was 19.0%. When the 2022 ACR/EULAR criteria were applied, the frequency of SSc-AAV-OS was 20.0%, which was much higher than 1.7% reported with previous criteria for

AAV. ANCA positivity contributed to the reclassification of SSc-AAV-OS more than ANCA negativity in SSc patients with signs suggestive of small- or medium-vessel vasculitis.

Conclusions: The frequency of SSc-AAV-OS in SSc patients with signs suggestive of small- or medium-vessel vasculitis at diagnosis was 20.0%. Therefore, we suggest that physicians should perform ANCA tests in SSc patients exhibiting signs suggestive of small- or medium-vessel vasculitis and apply the new criteria for AAV.

Keywords: Systemic sclerosis; Antibodies, antineutrophil cytoplasmic; Vasculitis

INTRODUCTION

Systemic sclerosis (SSc) is an autoimmune systemic connective tissue disease that can induce progressive fibrosis and vasculopathy affecting not only the skin but also major internal organs, leading to interstitial lung disease (ILD), cardiac diseases, renal crisis, gastrointestinal diseases, systemic calcinosis, digital vasculopathy, and pulmonary arterial hypertension [1]. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small vessel vasculitis that primarily affects capillaries, arterioles, and venules, and may occasionally involve medium arteries. AAV is categorized into three subtypes according to clinical, laboratory, radiological, and histological features: microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) [2,3].

Several previous studies support the presence of overlap syndrome (OS) of SSc and AAV (SSc-AAV-OS) in SSc patients. First, ANCA-associated glomerulonephritis was found in some SSc patients with renal crisis [4,5]. Second, ANCA positivity was found to be more closely related to ILD in SSc patients, regardless of AAV classification [6]. Third, proteinase 3 (PR3)-ANCA was shown to be associated with neuropathy in SSc patients, although it was not classified as having SSc-AAV-OS [7]. In addition, our previous study on ANCA positivity in Korean patients with SSc revealed that the detection rate of ANCA was 20.3%, and 1.7% of study subjects could finally be reclassified as having SSc-AAV-OS [8]. In the previous study, AAV was classified according to the algorithm for AAV and polyarteritis proposed by the European Medicines Agency in 2007 (the 2007 EMA algorithm) and the 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides (the 2012 CHCC definitions) [2,3].

Recently, a joint group of the American College of Rheumatology (ACR) and the European Alliance of Associations

for Rheumatology (EULAR) proposed new classification criteria for AAV (the 2022 ACR/EULAR criteria or the new criteria) for MPA, GPA, and EGPA. These criteria can be applied only to patients with evidence of small- or medium-vessel vasculitis, which is one of two mandatory requirements [9-11]. Therefore, it may be clinically significant to investigate the frequency of SSc-AAV-OS according to these new criteria; however, no study thereof has been reported to date. Hence, in this study, we selected SSc patients who exhibited signs suggestive of small- or medium-vessel vasculitis at SSc diagnosis from among the study subjects in our previous study [8]. We applied the 2022 ACR/EULAR criteria for AAV to selected SSc patients, investigated the frequency of SSc-AAV-OS, and compared it between the new and previous criteria.

METHODS

Study patients

We retrospectively screened 232 patients with SSc. The inclusion criteria were i) the first classification of SSc was made at the Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, from June 2004 to November 2020; ii) fulfillment of the classification criteria for SSc that were collaboratively proposed by the ACR and EULAR in 2013 (the 2013 ACR/EULAR criteria for SSc) [12]; iii) presence of well-written medical records sufficient for collecting and analyzing clinical data at diagnosis and during follow-up; iv) presence of ANCA test results; and v) presence of signs suggestive of small- or medium-vessel vasculitis at SSc diagnosis. The exclusion criteria were i) the presence of concomitant serious medical conditions mimicking SSc and AAV, such as malignancies and severe infectious diseases requiring hospitalization [13,14]; ii) presence of autoimmune diseases affecting

ANCA false positivity, such as inflammatory bowel diseases or primary sclerosing cholangitis [15]; iii) presence of administered drugs provoking ANCA false positivity, such as propylthiouracil and hydralazine [16,17]; iv) patients previously diagnosed with SSc-AAV-OS; and v) medical history of renal crisis that could not be differentiated from glomerulonephritis resulting from SSc-AAV-OS [4,5].

Among the 232 patients with SSc, 32 and 10 were excluded from this study because they lacked ANCA test results at diagnosis or did not fulfill the 2013 ACR/EULAR criteria for SSc, respectively. Among the remaining 190 patients, four, three, two, two, and two were excluded due to concomitant malignancies, Crohn's disease, ulcerative colitis, primary sclerosing cholangitis, and persistent exposure to PTU, respectively. Among the remaining 177 patients, three were excluded because they were diagnosed with SSc-AAV-OS before enrolment in this study. Among the remaining 174 patients, 105 who exhibited signs suggestive of small- or medium-vessel vasculitis were included in the study. Four patients had SSc-related renal crisis that was not definitely differentiated from AAV-associated renal vasculitis; however, they presented with ILD and were thus included in this study (Fig. 1).

The present study was approved by the Institutional Re-

view Board (IRB) of Severance Hospital (Seoul, Korea; IRB No. 4-2021- 0221). Given the retrospective design of the study and the use of anonymized patient data, the requirement for written informed consent was waived by the IRB.

Signs suggestive of small- or medium-vessel vasculitis

In this study, signs suggestive of small- or medium-vessel vasculitis included ILD, peripheral neuropathy, or suspected renal vasculitis. ILD was confirmed by high-resolution computed tomography on the lungs, and peripheral neuropathy was diagnosed through a nerve conduction velocity study. Suspected renal vasculitis was defined as hematuria with red blood cell dysmorphism positivity with a urine protein creatinine ratio > 0.5 g/g Cr or hematuria ≥ 2+ with proteinuria ≥ 2+ on a urine stick. The definition of suspected renal vasculitis in the 2007 EMA algorithm was RBC casts-related hematuria or > 10% dysmorphic RBC hematuria or 2+ hematuria and 2+ proteinuria on a urine stick [3].

Clinical data at diagnosis

Age and sex were collected as demographic data. The items of SSc-related manifestations were composed according to the 2013 ACR/EULAR criteria for SSc: differently weighted




Figure 1. Algorithm for patient selection. AAV, ANCA-associated vasculitis; ACR, the American College of Rheumatology; ANCA, anti-neutrophil cytoplasmic antibody; EULAR, European Alliance of Associations for Rheumatology; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; PTU, propylthiouracil; SSc, systemic sclerosis.

Table 1. Characteristics at diagnosis and during follow-up among SSc patients with signs suggestive of small- or medium-vessel vasculitis (n = 105)

Variable	Value
At the time of diagnosis	
Signs suggestive of small- or medium-vessel vasculitis, n (%)	
ILD	91 (86.7)
Peripheral neuropathy	15 (14.3)
Suspected renal vasculitis	30 (28.6)
Demographic data	
Age (yr), median (IQR)	53.0 (18.0)
Male sex, n (%)	18 (17.1)
SSc-related manifestations, n (%)	
Skin thickening of the fingers extending MCP joints	29 (27.6)
Sclerodactyly with/without puffy fingers	72 (68.6)
Fingertip lesions	21 (20.0)
Telangiectasia	3 (2.9)
Abnormal nailfold capillaries	14 (13.3)
Pulmonary arterial hypertension	38 (36.2)
Interstitial lung disease	91 (86.7)
Raynaud's phenomenon	47 (44.8)
SSc-related autoantibodies	
Anti-centromere	16 (15.2)
Anti-topoisomerase I	53 (50.5)
Total score	11 (3.0)
ANCA positivity, n (%)	
ANCA positivity	20 (19.0)
MPO-ANCA (or P-ANCA) positivity	16 (15.2)
PR3-ANCA (or C-ANCA) positivity	4 (3.8)
Laboratory results, median (IQR)	
White blood cell count (/mm ³)	7,300.0 (3,500)
Hemoglobin (g/dL)	12.8 (1.8)
Platelet count (× 1,000/mm ³)	268.5 (88.0)
Blood urea nitrogen (mg/dL)	11.3 (5.8)
Serum creatinine (mg/dL)	0.7 (0.2)
Aspartate aminotransferase (IU/L)	21.0 (10.0)
Alanine aminotransferase (IU/L)	15.0 (14.0)
Total protein (g/dL)	7.1 (1.0)
Serum albumin (g/dL)	4.1 (0.7)
During follow-up	
Poor outcomes	
ESRD, n (%)	4 (3.8)

Table 1. Continued

Variable	Value
Follow-up duration based on ESRD (mo), median (IQR)	62.5 (89.0)
CVA, n (%)	2 (1.9)
Follow-up duration based on CVA (mo), median (IQR)	62.5 (89.0)
ACS, n (%)	0 (0.0)
Follow-up duration based on ACS (mo), median (IQR)	N/A
All-cause mortality, n (%)	16 (15.2)
Follow-up duration based on all-cause mortality (mo), median (IQR)	62.5 (89.0)
Medications administered	
Glucocorticoids, n (%)	92 (87.6)
Cumulative dose ^{a)} (equivalent to prednisolone, mg), median (IQR)	1,085.0 (2816.9)
Immunosuppressive drugs, n (%)	
Cyclophosphamide	10 (9.5)
Rituximab	1 (1.0)
Mycophenolate mofetil	28 (26.7)
Azathioprine	37 (35.2)
Tacrolimus	17 (16.2)
Leflunomide	1 (1.0)
Methotrexate	13 (12.4)

ACS, acute coronary syndrome; ANCA, antineutrophil cytoplasmic antibody; C, cytoplasmic; CVA, cerebrovascular accident; ESRD, end-stage renal disease; ILD, interstitial lung disease; IQR, interquartile range; MCP, metacarpophalangeal; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; SSc, systemic sclerosis.

^{a)}The cumulative dose of glucocorticoids (equivalent to prednisolone, mg) was defined as that administered for 1 year before the last visit.

points are assigned to each item, and when the total score is ≥ 9 , SSc can be classified [12]. Perinuclear (P)-ANCA and cytoplasmic (C)-ANCA were measured using indirect immunofluorescence assays. Myeloperoxidase (MPO)-ANCA and PR3-ANCA were measured using the novel anchor-coated, highly sensitive Phadia ELiA immunoassay (Thermo Fisher Scientific/Phadia, Freiburg, Germany) and human native antigens on a Phadia250 analyzer [18]. The 2022 ACR/EULAR criteria for AAV recognize both P-ANCA or C-ANCA positivity and MPO-ANCA or PR3-ANCA positivity as ANCA positive [9-11]. Routine laboratory results were obtained (Table 1).

Clinical data during follow-up

End-stage renal disease (ESRD), cerebrovascular accident (CVA), acute coronary syndrome (ACS), and all-cause mor-

tality were investigated as poor outcomes of AAV during the follow-up duration. ESRD is clinically characterized by a glomerular filtration rate below 15 mL/min, necessitating

Table 2. Application of the 2022 ACR/EULAR criteria for MPA to SSc patients with ILD, polyneuropathy, or suspected renal vasculitis (n = 105)

Variable	Score	Value
At the time of enrolment in the cohort		
Items for the 2022 ACR/EULAR criteria for MPA and assigned scores to each item, n (%)		
Clinical criteria		
Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation)	-3	0 (0.0)
Laboratory, imaging and biopsy criteria		
MPO-ANCA (or P-ANCA) positivity	+6	16 (15.2)
Fibrosis or ILD on chest imaging	+3	91 (86.7)
Pauci-immune glomerulonephritis on biopsy	+3	0 (0.0)
PR3-ANCA (or C-ANCA) positivity	-1	4 (3.8)
Serum eosinophil count ≥ 1,000/μL	-4	5 (4.8)
Total score for 6 items above, median (IQR)		3.0 (0.0)
Patients with total score ≥ 5, n (%)		14 (13.3)

ACR, American College of Rheumatology; ANCA, antineutrophil cytoplasmic antibody; C, cytoplasmic; EULAR, European Alliance of Associations for Rheumatology; ILD, interstitial lung disease; IQR, interquartile range; MPA, microscopic polyangiitis; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; SSc, systemic sclerosis.

Table 3. Application of the 2022 ACR/EULAR criteria for GPA to SSc patients with ILD, polyneuropathy, or suspected renal vasculitis (n = 105)

Variable	Score	Value
At the time of diagnosis		
Items for the 2022 ACR/EULAR criteria for GPA and assigned scores to each item, n (%)		
Clinical criteria		
Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation)	+3	0 (0.0)
Cartilaginous involvement	+2	0 (0.0)
Conductive or sensorineural hearing loss	+1	1 (1.0)
Laboratory, imaging and biopsy criteria		
PR3-ANCA (or C-ANCA) positivity	+5	4 (3.8)
Pulmonary nodules, mass or cavitation	+2	57 (54.3)
Granuloma, granulomatous inflammation, or giant cells on biopsy	+2	4 (3.8)
Nasal/paranasal sinusitis or mastoiditis on imaging	+1	14 (13.3)
Pauci-immune glomerulonephritis on biopsy	+1	0 (0.0)
MPO-ANCA (or P-ANCA) positivity	-1	16 (15.2)
Serum eosinophil count ≥ 1,000/μL	-4	5 (4.8)
Total score for 10 items above, median (IQR)		1.0 (2.0)
Patients with total score ≥ 5, n (%)		5 (4.7)

ACR, American College of Rheumatology; ANCA, antineutrophil cytoplasmic antibody; C, cytoplasmic; EULAR, European Alliance of Associations for Rheumatology; GPA, granulomatosis with polyangiitis; ILD, interstitial lung disease; IQR, interquartile range; P, perinuclear; PR3, proteinase 3; MPO, myeloperoxidase; SSc, systemic sclerosis.

the initiation of renal replacement therapy. CVA is defined as an ischemic or hemorrhagic stroke. ACS is characterized by a collection of conditions, encompassing ST-elevation myocardial infarction, non-ST elevation myocardial infarction, and unstable angina. Among AAV patients with poor outcomes, the follow-up duration based on each poor outcome was defined as the period from AAV diagnosis to its first occurrence, whereas among patients without each poor outcome, it was defined as the period from AAV diagnosis to the last visit. The number of patients who received glucocorticoids and immunosuppressive drugs during the follow-up period was also assessed. Cumulative doses of glucocorticoids (equivalent to prednisolone, mg) were defined as the dose administered for 1 year before the last visit.

2022 ACR/EULAR classification criteria for AAV

The 2022 ACR/EULAR criteria for AAV encompass two changes relative to the 2007 EMA algorithm and 2012 CHCC definitions. First, the order of classification for EGPA, GPA, MPA, and unclassifiable vasculitis proposed by the 2007 EMA algorithm is omitted. Second, the criteria comprise several items to which differently weighted points are assigned as described in Tables 2-4. In addition, two mandatory requirements must be met before applying these

criteria: MPA or GPA can be classified with a total score of ≥ 5 . However, the classification of EGPA is only possible with a total score of ≥ 6 .

Statistical analyses

All statistical analyses were performed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, NY, USA). Continuous and categorical variables are expressed as medians with interquartile ranges and number (percentages), respectively. Significant differences between two categorical variables were analyzed using chi-square and Fisher's exact tests. Mann-Whitney U test was used to compare significant differences between two continuous variables. Statistical significance was set at $p < 0.05$.

RESULTS

Characteristics of SSc patients with signs suggestive of systemic vasculitis

Among the 105 SSc patients, 91, 15, and 30 had ILD, peripheral neuropathy, and suspected renal vasculitis, respectively, at diagnosis. The median age was 53.0 years, and 17.1% of the patients were men. The most common SSc-related manifestation was ILD (86.7%), followed by sclero-

Table 4. Application of the 2022 ACR/EULAR criteria for EGPA to SSc patients with ILD, polyneuropathy, or suspected renal vasculitis (n = 105)

Variable	Score	Value
At the time of diagnosis		
Items for the 2022 ACR/EULAR criteria for EGPA and assigned scores to each item, n (%)		
Clinical criteria		
Obstructive airway disease	+3	16 (15.2)
Nasal polyps	+3	2 (1.9)
Mononeuritis multiplex	+1	3 (2.9)
Laboratory, imaging and biopsy criteria		
Serum eosinophil count $\geq 1,000/\mu\text{L}$	+5	5 (4.8)
Extravascular eosinophilic-predominant inflammation on biopsy	+2	2 (1.9)
PR3-ANCA (or C-ANCA) positivity	-3	4 (3.8)
Hematuria	-1	88 (83.8)
Total score for 7 items above, median (IQR)		-1.0 (1.0)
Patients with total score ≥ 6 , n (%)		2 (1.9)

ACR, American College of Rheumatology; ANCA, antineutrophil cytoplasmic antibody; C, cytoplasmic; EGPA, eosinophilic granulomatosis with polyangiitis; EULAR, European Alliance of Associations for Rheumatology; ILD, interstitial lung disease; IQR, interquartile range; PR3, proteinase 3; SSc, systemic sclerosis.

Table 5. Comparison of the variables between patients with and without SSc-AAV-OS based on the 2022 ACR/EULAR criteria

Variable	Patients with SSc-AAV-OS (n = 21)	Patients without SSc-AAV-OS (n = 84)	p value
At the time of diagnosis			
Signs suggestive of small- or medium-vessel vasculitis, n (%)			
ILD	19 (90.5)	72 (85.7)	0.731
Peripheral neuropathy	4 (19.0)	11 (13.1)	0.494
Suspected renal vasculitis	10 (47.6)	32 (38.1)	0.426
Demographic data			
Age (yr), median (IQR)	52.0 (19.0)	53.0 (18.0)	0.519
Male sex, n (%)	2 (9.5)	16 (19.0)	0.517
SSc-related manifestations, n (%)			
Skin thickening of the fingers extending MCP joints	5 (23.8)	24 (28.6)	0.662
Sclerodactyly with/without puffy fingers	15 (71.4)	57 (67.9)	0.753
Fingertip lesions	4 (19.0)	17 (20.2)	> 0.999
Telangiectasia	1 (4.8)	2 (2.4)	0.492
Abnormal nailfold capillaries	3 (14.3)	11 (13.1)	> 0.999
Pulmonary arterial hypertension	9 (42.9)	29 (34.5)	0.477
Interstitial lung disease	19 (90.5)	72 (85.7)	0.731
Raynaud's phenomenon	8 (38.1)	39 (46.4)	0.492
SSc-related autoantibodies			
Anti-centromere	4 (19.0)	12 (14.3)	0.734
Anti-topoisomerase I	10 (47.6)	43 (51.2)	0.770
Total score	11.0 (3.0)	11.0 (3.0)	0.641
ANCA positivity, n (%)			
ANCA positivity	18 (85.7)	2 (2.4)	< 0.001
MPO-ANCA (or P-ANCA) positivity	14 (66.7)	2 (2.4)	< 0.001
PR3-ANCA (or C-ANCA) positivity	4 (19.0)	0 (0.0)	0.001
Laboratory results, median (IQR)			
White blood cell count (/mm ³)	7,800.0 (4,200)	7,200.0 (3,200)	0.363
Hemoglobin (g/dL)	12.5 (1.9)	12.8 (1.6)	0.292
Platelet count (× 1,000/mm ³)	269.0 (114.0)	268.0 (82.0)	0.946
Blood urea nitrogen (mg/dL)	11.0 (7.7)	11.5 (5.2)	0.644
Serum creatinine (mg/dL)	0.6 (0.3)	0.7 (0.2)	0.235
Aspartate aminotransferase (IU/L)	20.0 (24.0)	21.0 (7.0)	0.919
Alanine aminotransferase (IU/L)	16.0 (22.0)	15.0 (11.0)	0.094
Total protein (g/dL)	7.1 (1.2)	7.1 (1.0)	0.836
Serum albumin (g/dL)	4.1 (0.7)	4.1 (0.7)	0.795
During follow-up			
Poor outcomes			
ESRD, n (%)	1 (4.8)	3 (3.6)	> 0.999
Follow-up duration based on ESRD (mo), median (IQR)	59.0 (69.0)	69.0 (90.0)	0.857
CVA, n (%)	1 (4.8)	1 (1.2)	0.362

Table 5. Continued

Variable	Patients with SSc-AAV-OS (n = 21)	Patients without SSc-AAV-OS (n = 84)	p value
Follow-up duration based on CVA (mo), median (IQR)	62.0 (69.0)	69.0 (90.0)	0.798
ACS, n (%)	0 (0.0)	0 (0.0)	
Follow-up duration based on ACS (mo), median (IQR)	N/A	N/A	
All-cause mortality, n (%)	2 (9.5)	14 (16.7)	0.518
Follow-up duration based on all-cause mortality (mo), median (IQR)	62.0 (69.0)	69.0 (90.0)	0.829
Medications administered			
Glucocorticoids, n (%)	19 (90.5)	73 (86.9)	> 0.999
Cumulative dose ^{a)} (equivalent to prednisolone), median (IQR)	1,650.0 (5,111.8)	840.0 (2,450.0)	0.066
Immunosuppressive drugs, n (%)			
Cyclophosphamide	1 (4.8)	9 (10.7)	0.683
Rituximab	1 (4.8)	0 (0.0)	0.200
Mycophenolate mofetil	6 (28.6)	22 (26.2)	0.825
Azathioprine	6 (28.6)	31 (36.9)	0.475
Tacrolimus	5 (23.8)	12 (14.3)	0.289
Leflunomide	0 (0.0)	1 (1.2)	> 0.999
Methotrexate	2 (9.5)	11 (13.1)	> 0.999

AAV, ANCA-associated vasculitis; ACR, American College of Rheumatology; ACS, acute coronary syndrome; ANCA, antineutrophil cytoplasmic antibody; C, cytoplasmic; CVA, cerebrovascular accident; ESRD, end-stage renal disease; EULAR, European Alliance of Associations for Rheumatology; ILD, interstitial lung disease; IQR, interquartile range; MCP, metacarpophalangeal; MPO, myeloperoxidase; OS, overlap syndrome; P, perinuclear; PR3, proteinase 3; SSc, systemic sclerosis.

^{a)}The cumulative dose of glucocorticoids (equivalent to prednisolone, mg) was defined as that administered for 1 year before the last visit.

dactly with or without puffy fingers (68.6%). The overall detection rate of ANCA was 19.0%; 16 and 4 patients had MPO-ANCA (or P-ANCA) and PR3-ANCA (or C-ANCA), respectively. During follow-up, four (3.8%) and two patients (1.9%) had ESRD and CVA, respectively, and 16 died after SSc diagnosis. Ninety-two patients (87.6%) received glucocorticoids, with a median cumulative dose of 1,085 mg. The most frequently administered immunosuppressive drug was azathioprine (35.2%), followed by mycophenolate mofetil (26.7%) (Table 1).

Application of the 2022 ACR/EULAR criteria for MPA

Regarding clinical criteria, none met the item of nasal involvement. Regarding laboratory, imaging, and biopsy criteria, the most frequently met item was fibrosis or ILD on chest imaging (86.7%), followed by MPO-ANCA (or P-ANCA) positivity (15.2%). None met the item of pauci-immune glomerulonephritis. Among the 105 SSc patients, 14

(13.3%) achieved a total score ≥ 5 and thus were reclassified as having MPA [9] (Table 2).

Application of the 2022 ACR/EULAR criteria for GPA

Regarding clinical criteria, one patient (1.0%) met the item of conductive or sensorineural hearing loss. Regarding laboratory, imaging, and biopsy criteria, the item of pulmonary nodules, mass, or cavitation (54.3%) was most often met. None met the item of pauci-immune glomerulonephritis. Four patients received +5 points for PR3-ANCA (or C-ANCA) positivity, whereas 16 patients received -1 point for MPO-ANCA (or P-ANCA) positivity. Among the 105 SSc patients, 5 (4.7%) achieved a total score ≥ 5 and thus were reclassified as having GPA [10] (Table 3).

Application of the 2022 ACR/EULAR criteria for EGPA

Regarding clinical criteria, 16, 2, and 3 patients met the items

of obstructive airway disease, nasal polyps, and mononeuritis multiplex, respectively. Regarding laboratory, imaging, and biopsy criteria, 4 and 88 patients received -3 and -1 points for the items of PR3-ANCA (or C-ANCA) positivity and hematuria, respectively. Among the 105 SSc patients, 2 (1.9%) achieved a total score ≥ 6 and thus were reclassified as having EGPA [11] (Table 4).

Frequency of SSc-AAV-OS

Among the 105 SSc patients with signs suggestive of small- or medium-vessel vasculitis, 21 were reclassified as having AAV. Of the 21 patients reclassified as having SSc-AAV-OS, none had two AAV subtypes simultaneously. The overall frequency of SSc-AAV-OS was 20.0%.

Comparative analysis of variables between patients with and without SSc-AAV-OS

Among variables at diagnosis, ANCA, MPO-ANCA (P-ANCA), and PR3-ANCA (C-ANCA) were detected more frequently in patients with SSc-AAV-OS than those without. Interestingly, no significant differences were observed in signs suggestive of small- or medium-vessel vasculitis between the two groups. Hence, ANCA positivity contributed to the reclassification of SSc-AAV-OS more than ANCA negativity in SSc patients with signs suggestive of small- or medium-vessel vasculitis. In this study, ANCA positivity was not significantly associated with ILD. This was because some SSc patients without ILD were excluded from this study owing to mandatory requirements. Among variables during follow-up, no significant differences were observed between the two groups (Table 5).

DISCUSSION

This study investigated the frequency of patients who could be reclassified as having SSc-AAV-OS according to the 2022 ACR/EULAR criteria for AAV among SSc patients with signs suggestive of small- or medium-vessel vasculitis at diagnosis. Among the 105 SSc patients, 14 (13.3%), 5 (4.7%), and 2 (1.9%) were reclassified as having SSc-MPA-OS, SSc-GPA-OS, and SSc-EGPA-OS, respectively. Therefore, we revealed that the overall frequency of SSc-AAV-OS was 20.0%, which was much higher than 1.7% reported for previous criteria for AAV among the SSc patients included in our previous study [8]. In addition, we found that ANCA

positivity contributed to the reclassification of SSc-AAV-OS more than ANCA negativity in SSc patients with signs suggestive of small- or medium-vessel vasculitis. Therefore, we concluded that at the time of SSc diagnosis, approximately a fifth of SSc patients exhibiting ILD, peripheral neuropathy, or suspected renal vasculitis could be reclassified as having SSc-AAV-OS, and MPA was the most common subtype of AAV.

Regarding the mechanism of SSc-AAV-OS among SSc patients, we propose two hypotheses. One possible mechanism is the occurrence of ANCA-induced SSc-AAV-OS. It can be assumed that the inflammatory process of SSc may prime neutrophils and produce circulating pathogenic ANCA, which may activate primed neutrophils and develop AAV [19,20]. A previous study reporting that ANCA was detected in up to 12% of SSc patients can support our hypothesis [21]. The other possible mechanism is vasculopathy-induced SSc-AAV-OS occurrence, regardless of ANCA positivity, because endothelial dysregulation and its-related vasculopathy play important roles in the pathogenesis of both SSc and AAV. As a result, SSc and AAV may share various clinical manifestations, such as ILD, digital vasculitis, or kidney involvement [1]. It can be challenging to distinguish obstructive vasculopathy, a prominent feature of SSc, from necrotizing vasculitis, a feature of AAV, especially in early stages, and these pathological findings can coexist, leading to SSc-AAV-OS [20,22]. This study included only SSc patients with signs suggestive of small- and medium-vessel vasculitis at diagnosis, which may explain the relatively high frequency of SSc-AAV-OS, compared to previous studies. This finding may also emphasize the necessity of ANCA testing in patients with signs suggestive of vasculitis.

ILD, peripheral neuropathy, and suspected renal vasculitis were defined as signs suggestive of small- or medium-vessel vasculitis in this study. ILD can occur in patients with SSc and in patients with AAV. Both usual interstitial pneumonia and nonspecific interstitial pneumonia patterns are observed in AAV-related ILD, and similar patterns are also observed in SSc-related ILD [23,24]. The differentiation between SSc-related ILD and AAV-related ILD is difficult by imaging alone. Differentiation between SSc renal crisis and ANCA-associated glomerulonephritis can be challenging in patients with progressive acute renal failure [5]. In a retrospective study, it is reasonable to confirm the involvement of the lungs, kidneys, and peripheral nervous system to find a sign of vasculitis.

In this study, the frequency of SSc-AAV-OS was 20.0%, which is significantly higher than the 1.7% frequency reported in our previous study. There are two possible explanations for this finding. First, the patient population in this study was more narrowly defined. In the previous study, all patients with SSc who underwent ANCA tests were included, while in this study, only patients with SSc who had vasculitis signs in the lungs, kidneys, and peripheral nervous system were included. This narrower patient population may have resulted in a higher proportion of patients classified as overlapping. Second, the diagnostic criteria for AAV were different in the two studies. In the previous study, AAV was classified using the 2007 EMA algorithm, while in this study, AAV was classified using the 2022 ACR/EULAR criteria. The 2022 ACR/EULAR criteria for AAV assign a higher score to ANCA positivity, resulting in an increased share of ANCA positive patients being diagnosed with AAV. In a previous study, 3 of 36 (8.3%) ANCA positive patients with SSc were classified as SSc-AAV-OS. In this study, 18 out of 20 (90.0%) ANCA positive patients with SSc and vasculitis features were classified as SSc-AAV-OS. Additionally, the inclusion of ILD in the 2022 ACR/EULAR criteria may have resulted in a higher number of patients classified as overlapping SD of SSc and AAV.

In this study, 105 SSc patients with the signs suggestive of small- or medium-vessel vasculitis were included. Five patients had all three signs, and 26 patients had two or more signs (Supplementary Fig. 1). Of the 5 patients with all three signs, two (40.0%) were reclassified as having SSc-AAV-OS, and six (23.1%) of 26 patients with two or more signs were reclassified as having SSc-AAV-OS. Among the 79 patients with only one sign, 15 (19.0%) were reclassified as having SSc-AAV-OS. Although the proportion of ANCA positivity appeared to provide a greater contribution to the reclassification, as the number of signs suggestive of small- or medium-vessel vasculitis in SSc patients increased, the rate of classification as AAV tended to increase. However, statistical significance was difficult to confirm because of the small number of patients.

In this study, two patients with ANCA positivity could not be reclassified as having SSc-AAV-OS. The presence of serum eosinophilia precluded classification as MPA or GPA. Furthermore, the absence of other characteristic features of EGPA, such as obstructive airway disease and nasal polyps, hindered its classification as EGPA (Supplementary Table 1). Conversely, three patients without ANCA could be reclassified

as having SSc-AAV-OS. Patient 3 exhibited pulmonary lesions indicative of GPA, confirmed granuloma on biopsy, and paranasal sinusitis on imaging, despite testing negative for ANCA. Thus, this patient could be appropriately classified as GPA. Patient 4 presented with obstructive airway disease and serum eosinophilia, aligning with the characteristic features of EGPA. Therefore, this patient could be classified as EGPA. Patient 5 displayed mononeuritis multiplex, serum eosinophilia, and biopsy findings showing extravascular eosinophilic-predominant inflammation. These clinical manifestations support the classification of this patient as EGPA (Supplementary Table 2).

At the start of this study, three patients who were previously diagnosed with SSc-AAV-OS according to the 2007 EMA algorithm and the 2012 CHCC definitions were excluded from this study. We wondered which subtype of AAV they would be reclassified as according to the new criteria for AAV. All three patients presented with ILD or glomerulonephritis, indicating the presence of small- or medium-vessel vasculitis features. When the 2022 ACR/EULAR criteria for MPA were applied [9], patient A received +6, +3, and +3 points for the items of MPO-ANCA (or P-ANCA) positivity, ILD on imaging, and pauci-immune glomerulonephritis on biopsy, respectively. Patient A achieved a total score of 12, and thus, could be reclassified as having SSc-MPA-OS. On the other hand, patient B received +6, and +3 points for the items of MPO-ANCA (or P-ANCA) positivity and ILD on imaging. Patient B achieved the total score of 9 and thus could also be reclassified as having SSc-MPA-OS. When the 2022 ACR/EULAR criteria for GPA were applied [10], patient C received +5, +2, +2, and +1 points based on the items of PR3-ANCA (or C-ANCA) positivity, pulmonary lesions suggesting GPA, granuloma on biopsy, and paranasal sinusitis; however, patient C received -4 points for the item of serum eosinophilia. Finally, patient C achieved a total score of 6, and thus could also be reclassified as having SSc-GPA-OS. In contrast, when the 2022 ACR/EULAR criteria for EGPA were applied [11], none met the criteria (Supplementary Table 3).

Interestingly, 21 SSc patients who had not been classified as having SSc-AAV-OS according to the 2007 EMA algorithm modified by the 2012 CHCC definitions in our previous study [2,3,8] met the 2022 ACR/EULAR criteria for AAV and could be reclassified as having SSc-AAV-OS. We analyzed how they were newly reclassified according to AAV subtypes and signs suggestive of small- or medium-vessel vasculitis. Among the 14 patients newly diagnosed with

SSc-MPA-OS, 13 patients achieved a total score of 9 points due to MPO-ANCA (or P-ANCA) positivity (+3) and ILD (+3). One patient with mononeuritis multiplex was classified as having SSc-AAV-OS by the item of MPO-ANCA (or P-ANCA) positivity alone. According to the 2007 EMA algorithm modified by the 2012 CHCC definitions, 13 patients with ILD and one with mononeuritis multiplex could not be reclassified as having MPA.

Among the five patients newly diagnosed with SSc-GPA-OS, four patients with ILD achieved the total score of 5 points for the item of PR3-ANCA (or C-ANCA) positivity alone. Whereas, one patient, who exhibited ILD but did not have PR3-ANCA (or C-ANCA), could be reclassified as having SSc-GPA-OS by granuloma (+2), paranasal sinusitis (+1), and lung nodule (+2). In particular, according to the 2007 EMA algorithm modified by the 2012 CHCC definitions, the last patient could not be reclassified as having GPA. This was because previous studies have delineated the histological features of GPA as necrotizing granulomatous inflammation, necrotizing vasculitis, and necrotizing glomerulonephritis, but not as granuloma alone. Furthermore, the patient showed a GPA surrogate marker of lung nodules but did not show ANCA positivity. Among the two patients newly diagnosed with SSc-EGPA-OS, one patient achieved a total score of +8 points with the items of asthma (+3) and serum eosinophilia (+5), and the other patient achieved the total score of +6 points with the items of serum eosinophilia (+5) and mononeuritis multiplex (+1). Therefore, they could be reclassified as having EGPA. However, they did not satisfy the 2007 EMA algorithm modified by the 2012 CHCC definitions for EGPA. Therefore, it was concluded that the 2022 ACR/EULAR criteria are more sensitive than previous criteria in discovering AAV in SSc patients (Supplementary Table 4).

Although SSc-AAV-OS is a rare condition, its diagnosis is crucial due to potential variations in patient treatment. For instance, a patient presenting with both SSc and progressive acute kidney injury may be due to SSc renal crisis, but if it is ANCA-associated glomerulonephritis, the treatment approach would differ. Additionally, if healthcare providers do not suspect AAV in such cases, there is a high likelihood that they may overlook additional tests like ANCA testing and renal biopsy, leading to challenges in early diagnosis and treatment. Our study found no statistically significant difference between SSc-AAV-OS and non-AAV groups. However, upon examining the cumulative steroid dosage administered during the 1-year period before the last visit, we

observed that the SSc-AAV-OS group utilized 1,650.0 mg of prednisolone, which is approximately 1.96 times higher than the 840.0 mg used by the non-AAV group. Hence, further research with a larger patient cohort is necessary to confirm the clinical distinctions of the SSc-AAV-OS group.

This study has several advantages, given that the OS of AAV and connective tissue diseases may occur at a low frequency. First, this study applied the 2022 ACR/EULAR criteria for AAV to SSc patients and investigated the frequency of SSc-AAV-OS for the first time. Second, this study strictly included only patients carrying signs suggestive of small- or medium-vessel vasculitis. Third, this study performed subgroup analyses according to each AAV subtype using the new criteria. Fourth, this study compared the sensitivity of the new and previous criteria to discover SSc-AAV-OS. We believe that this study provides new insights into SSc-AAV-OS. Meanwhile, this study also has several limitations. The number of patients in a single-center study was not large enough to generalize the results and apply them to SSc patients immediately. The retrospective study design could not rule out the possibility of missing data when collecting information which could hinder accurately predicting poor prognosis or medication history. Since this was a retrospective study, there was no opportunity to differentiate ILD or renal vasculitis histologically. The potential for the inclusion of patients with SSc who possessed ANCA test results makes it challenging to rule out the possibility of selection bias in this study. Moreover, owing to these limitations, this study could not suggest management strategies for patients with SSc-AAV-OS. A prospective future study with more SSc patients with signs suggestive of vasculitis will provide more reliable information on SSc-AAV-OS and will help to establish management strategies for patients with SSc-AAV-OS.

KEY MESSAGE

1. The overall frequency of SSc-AAV-OS among SSc patients with signs suggestive of small- or medium-vessel vasculitis at diagnosis was 20.0% according to the 2022 ACR/EULAR criteria for AAV.
2. Physicians should perform ANCA tests for SSc patients exhibiting signs suggestive of small- or medium-vessel vasculitis and apply the new criteria for AAV.

REFERENCES

1. Denton CP, Khanna D. Systemic sclerosis. *Lancet* 2017;390:1685-1699.
2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013;65:1-11.
3. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis* 2007;66:222-227.
4. Kant S, Shah AA, Hummers LK, Wigley FM, Geetha D. ANCA-associated vasculitis in scleroderma: a renal perspective. *Clin Nephrol* 2018;90:413-418.
5. Wu R, Su J, Zou YR, Zhu J. ANCA-associated vasculitis overlaps with systemic sclerosis: a case report and literature review. *Eur J Med Res* 2021;26:30.
6. Moxey J, Huq M, Proudman S, et al. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. *Arthritis Res Ther* 2019;21:57.
7. Radwan Y, Berini S, Ernste F, Makol A. Proteinase 3 (PR3)-antineutrophil cytoplasmic antibody (ANCA)-associated vasculitic neuropathy in diffuse cutaneous systemic sclerosis: a rare duo. *BMJ Case Rep* 2019;12:e232987.
8. Ha JW, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW. Significance of antineutrophil cytoplasmic antibody positivity in patients with systemic sclerosis: a single-centre pilot study in Korea. *Clin Exp Rheumatol* 2021;39 Suppl 131:111-118.
9. Suppiah R, Robson JC, Grayson PC, et al.; DCVAS INVESTIGATORS. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. *Ann Rheum Dis* 2022;81:321-326.
10. Robson JC, Grayson PC, Ponte C, et al.; DCVAS Investigators. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. *Ann Rheum Dis* 2022;81:315-320.
11. Grayson PC, Ponte C, Suppiah R, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. *Ann Rheum Dis* 2022;81:309-314.
12. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. *Ann Rheum Dis* 2013;72:1747-1755.
13. Do H, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW. Cancer-associated vasculitides: a single-centre case series. *Clin Rheumatol* 2023;42:151-158.
14. Phatak S, Aggarwal A, Agarwal V, Lawrence A, Misra R. Antineutrophil cytoplasmic antibody (ANCA) testing: audit from a clinical immunology laboratory. *Int J Rheum Dis* 2017;20:774-778.
15. Lee WI, Subramaniam K, Hawkins CA, Randall KL. The significance of ANCA positivity in patients with inflammatory bowel disease. *Pathology* 2019;51:634-639.
16. Wong AH, Wong WK, Looi LM, Ratnasingam J, Lim SK. Propylthiouracil-induced antineutrophil cytoplasmic antibodies-associated vasculitis with renal and lung involvement. *Case Rep Nephrol Dial* 2022;12:105-111.
17. Alawneh D, Edrees A. Hydralazine-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a case report and literature review. *Cureus* 2022;14:e24132.
18. Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. *Nat Rev Rheumatol* 2017;13:683-692.
19. Choi CB, Park YB, Lee SW. Antineutrophil cytoplasmic antibody-associated vasculitis in Korea: a narrative review. *Yonsei Med J* 2019;60:10-21.
20. Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. *Nat Rev Dis Primers* 2020;6:71.
21. Quéméneur T, Mouthon L, Cacoub P, et al. Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. *Medicine (Baltimore)* 2013;92:1-9.
22. Asano Y, Sato S. Vasculopathy in scleroderma. *Semin Immunopathol* 2015;37:489-500.
23. Ha JW, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW. Incidence and patterns of interstitial lung disease and their clinical impact on mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis: Korean single-centre observational study. *J Immunol Res* 2022;2022:2499404.
24. Ha JW, Hong YJ, Cha HJ, et al. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and interstitial lung disease in systemic sclerosis. *Sci Rep* 2022;12:19253.

Received : July 5, 2023

Revised : September 4, 2023

Accepted : September 9, 2023

Correspondence to

Sang-Won Lee, M.D., Ph.D.

Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea

Tel: +82-2-2228-1987, Fax: +82-2-393-6884

E-mail: sangwonlee@yuhs.ac

<https://orcid.org/0000-0002-8038-3341>

CRediT authorship contributions

Jang Woo Ha: conceptualization, investigation, data curation, formal analysis, writing - original draft; Jung Yoon Pyo: conceptualization, investigation, data curation, writing - original draft; Sung Soo Ahn: investigation, data curation; Jason Jungsik Song: formal analysis, writing


- review & editing; Yong-Beom Park: formal analysis, writing - review & editing; Sang-Won Lee: conceptualization, formal analysis, writing - original draft, writing - review & editing, supervision, funding acquisition

Conflicts of interest

The authors disclose no conflicts.

Funding

This study received funding from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare (HI14C1324), Handok Inc., Seoul, Republic of Korea (HANDOK 2021-006), and from CELLTRION PHARM, Inc. Chungcheongbuk-do, Republic of Korea (NCR 2019-6).



Supplementary Figure 1. Signs suggestive of small- or medium-vessel vasculitis.

Supplementary Table 1. Itemized analysis of SSc patients who had ANCA but were not reclassified as having the overlap syndrome of SSc with AAV according to the 2022 ACR/EULAR criteria for MPA, GPA, or EGPA (n = 2)

Patients number	Scores based on the 2022 ACR/EULAR criteria for MPA	1 (-3)	2 (+6)	3 (+3)	4 (+3)	5 (-1)	6 (-4)
1	2	0	1	0	0	0	1
2	2	0	1	0	0	0	1

1 = Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation); 2 = MPO-ANCA (or P-ANCA) positivity; 3 = Fibrosis or interstitial lung disease on chest imaging; 4 = Pauci-immune glomerulonephritis on biopsy; 5 = PR3-ANCA (or C-ANCA) positivity; 6 = Serum eosinophil count $\geq 1,000/\mu\text{L}$.

Patients number	Scores based on the 2022 ACR/EULAR criteria for GPA	1 (+3)	2 (+2)	3 (+1)	4 (+5)	5 (+2)	6 (+2)	7 (+1)	8 (+1)	9 (-1)	10 (-4)
1	-3	0	0	0	0	1	0	0	0	1	1
2	-3	0	0	0	0	1	0	0	0	1	1

1 = Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation); 2 = Cartilaginous involvement; 3 = Conductive or sensorineural hearing loss; 4 = PR3-ANCA (or C-ANCA) positivity; 5 = Pulmonary nodules, mass or cavitation; 6 = Granuloma, granulomatous inflammation, or giant cells on biopsy; 7 = Nasal/paranasal sinusitis or mastoiditis on imaging; 8 = Pauci-immune glomerulonephritis on biopsy; 9 = MPO-ANCA (or P-ANCA) positivity; 10 = Serum eosinophil count $\geq 1,000/\mu\text{L}$.

Patients number	Scores based on the 2022 ACR/EULAR criteria for EGPA	1 (+3)	2 (+3)	3 (+1)	4 (+5)	5 (+2)	6 (-3)	7 (-1)
1	4	0	0	0	1	0	0	1
2	4	0	0	0	1	0	0	1

1 = obstructive airway disease; 2 = nasal polyps; 3 = mononeuritis multiplex; 4 = Serum eosinophil count $\geq 1,000/\mu\text{L}$; 5 = Extravascular eosinophilic-predominant inflammation on biopsy; 6 = PR3-ANCA (or C-ANCA) positivity; 7 = haematuria.

SSc, systemic sclerosis; ILD, interstitial lung disease; ACR, American College of Rheumatology; EULAR, European Alliance of Associations for Rheumatology; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, Eosinophilic granulomatosis with polyangiitis; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; ANCA, antineutrophil cytoplasmic antibody; C, cytoplasmic.

Supplementary Table 2. Itemized analysis of SSc patients who did not have ANCA but reclassified as having the overlap syndrome of SSc with AAV according to the 2022 ACR/EULAR criteria for MPA, GPA, or EGPA (n = 3) (patient 3 = GPA, patients 4 and 5 = EGPA)

Patients number	Scores based on the 2022 ACR/EULAR criteria for MPA	1 (-3)	2 (+6)	3 (+3)	4 (+3)	5 (-1)	6 (-4)
3	3	0	0	1	0	0	0
4	-1	0	0	1	0	0	1
5	-4	0	0	0	0	0	1

1 = Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation); 2 = MPO-ANCA (or P-ANCA) positivity; 3 = Fibrosis or interstitial lung disease on chest imaging; 4 = Pauci-immune glomerulonephritis on biopsy; 5 = PR3-ANCA (or C-ANCA) positivity; 6 = Serum eosinophil count $\geq 1,000/\mu\text{L}$.

Patients number	Scores based on the 2022 ACR/EULAR criteria for GPA	1 (+3)	2 (+2)	3 (+1)	4 (+5)	5 (+2)	6 (+2)	7 (+1)	8 (+1)	9 (-1)	10 (-4)
3	5	0	0	0	0	1	1	1	0	0	0
4	-2	0	0	0	0	1	0	0	0	0	1
5	-3	0	0	0	0	0	0	1	0	0	1

1 = Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation); 2 = Cartilaginous involvement; 3 = Conductive or sensorineural hearing loss; 4 = PR3-ANCA (or C-ANCA) positivity; 5 = Pulmonary nodules, mass or cavitation; 6 = Granuloma, granulomatous inflammation, or giant cells on biopsy; 7 = Nasal/paranasal sinusitis or mastoiditis on imaging; 8 = Pauci-immune glomerulonephritis on biopsy; 9 = MPO-ANCA (or P-ANCA) positivity; 10 = Serum eosinophil count $\geq 1,000/\mu\text{L}$.

Patients number	Scores based on the 2022 ACR/EULAR criteria for EGPA	1 (+3)	2 (+3)	3 (+1)	4 (+5)	5 (+2)	6 (-3)	7 (-1)
3	2	1	0	0	0	0	0	1
4	7	1	0	0	1	0	0	1
5	7	0	0	1	1	1	0	1

1 = obstructive airway disease; 2 = nasal polyps; 3 = mononeuritis multiplex; 4 = Serum eosinophil count $\geq 1,000/\mu\text{L}$; 5 = Extravascular eosinophilic-predominant inflammation on biopsy; 6 = PR3-ANCA (or C-ANCA) positivity; 7 = hematuria.

SSc, systemic sclerosis; ILD, interstitial lung disease; ACR, American College of Rheumatology; EULAR, European Alliance of Associations for Rheumatology; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, Eosinophilic granulomatosis with polyangiitis; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; ANCA, antineutrophil cytoplasmic antibody; C, cytoplasmic.

Supplementary Table 3. Itemized analysis of SSc patients previously diagnosed with the overlap syndrome of SSc with AAV (n = 3): these patients were not included in this study

Patients number	Scores based on the 2022 ACR/EULAR criteria for MPA	1 (-3)	2 (+6)	3 (+3)	4 (+3)	5 (-1)	6 (-4)
A	12	0	1	1	1	0	0
B	9	0	1	1	0	0	0
C	-2	0	0	1	0	1	1

1 = Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation); 2 = MPO-ANCA (or P-ANCA) positivity; 3 = Fibrosis or interstitial lung disease on chest imaging; 4 = Pauci-immune glomerulonephritis on biopsy; 5 = PR3-ANCA (or C-ANCA) positivity; 6 = Serum eosinophil count $\geq 1,000/\mu\text{L}$.

Patients number	Scores based on the 2022 ACR/EULAR criteria for GPA	1 (+3)	2 (+2)	3 (+1)	4 (+5)	5 (+2)	6 (+2)	7 (+1)	8 (+1)	9 (-1)	10 (-4)
A	3	0	0	0	0	1	0	1	1	1	0
B	2	0	0	1	0	1	0	0	0	1	0
C	6	0	0	0	1	1	1	1	0	0	1

1 = Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation); 2 = Cartilaginous involvement; 3 = Conductive or sensorineural hearing loss; 4 = PR3-ANCA (or C-ANCA) positivity; 5 = Pulmonary nodules, mass or cavitation; 6 = Granuloma, granulomatous inflammation, or giant cells on biopsy; 7 = Nasal/paranasal sinusitis or mastoiditis on imaging; 8 = Pauci-immune glomerulonephritis on biopsy; 9 = MPO-ANCA (or P-ANCA) positivity; 10 = Serum eosinophil count $\geq 1,000/\mu\text{L}$.

Patients number	Scores based on the 2022 ACR/EULAR criteria for EGPA	1 (+3)	2 (+3)	3 (+1)	4 (+5)	5 (+2)	6 (-3)	7 (-1)
A	-1	0	0	0	0	0	0	1
B	-1	0	0	0	0	0	0	1
C	2	0	0	1	1	0	1	1

1 = obstructive airway disease; 2 = nasal polyps; 3 = mononeuritis multiplex; 4 = Serum eosinophil count $\geq 1,000/\mu\text{L}$; 5 = Extravascular eosinophilic-predominant inflammation on biopsy; 6 = PR3-ANCA (or C-ANCA) positivity; 7 = hematuria.

SSc, systemic sclerosis; ILD, interstitial lung disease; ACR, American College of Rheumatology; EULAR, European Alliance of Associations for Rheumatology; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, Eosinophilic granulomatosis with polyangiitis; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; ANCA, antineutrophil cytoplasmic antibody; C, cytoplasmic.

Supplementary Table 4. Subgroup analysis of 21 patients who were newly reclassified as having SSc-AAV-OS according to AAV subtypes and each sign suggestive of small- or medium-vessel vasculitis

AAV type	Signs suggestive of vasculitis	Items met
MPA	13 patients with ILD	MPO-ANCA (or P-ANCA) positivity (+6) and ILD (+3)
	1 patient with mononeuritis multiplex	MPO-ANCA (or P-ANCA) positivity (+6)
GPA	4 patients with ILD	PR3-ANCA (or C-ANCA) positivity (+5)
	1 patient with ILD	PR3-ANCA (or C-ANCA) negativity, granuloma ^{a)} (+2), paranasal sinusitis (+1), and lung nodule (+2)
EGPA	1 patient with ILD	Asthma (+3), and serum eosinophilia (+5)
	1 patient with mononeuritis multiplex	No asthma, serum eosinophilia (+5), and mononeuritis multiplex (+1)

SSc, systemic sclerosis; AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; OS, overlap syndrome; ILD, interstitial lung disease; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic.

^{a)}The 2022 ACR/EULAR criteria describe the item related to granuloma as granuloma, granulomatous inflammation, or giant cells on biopsy, whereas, the 2012 CHCC definitions delineate the histopathologic feature of GPA as necrotising granulomatous inflammation, necrotising vasculitis, and necrotising glomerulonephritis.